Novartis AG - ADR Peer Comparison
$161.93
$-3.05
(-1.85%)
As on 05-Nov-2026 16:10EST
Market cap
$304,257 Mln
Revenue (TTM)
$56,306 Mln
P/E Ratio
30.7
P/B Ratio
7.9
Div. Yield
2.9 %
Edit
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
304,257 | 1,262,667 | 662,492 | 361,021 | 211,814 |
Revenue ($ Mln) |
56,306 | 86,462 | 99,335 | 67,302 | 30,987 |
Net Profit ($ Mln) |
10,033.05 | 27,579.70 | 16,095.00 | 2,453.00 | -3,863.00 |
Net Margin (%) |
17.82 | 31.90 | 16.20 | 3.64 | -12.47 |
RoE (%) |
26.54 | 77.18 | 19.78 | 10.72 | -21.14 |
Price to Earnings |
30.74 | 46.11 | 41.76 | 116.13 | 17.74 |
Price-To-Book |
7.92 | 31.35 | 8.00 | 8.29 | 16.24 |
Income Statement ($ Mln)
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
56,305.86 | 86,462.00 | 99,335.00 | 67,302.00 | 30,987.00 |
|
Cost of Revenue
|
14,289.25 | 14,149.70 | 30,982.00 | 15,512.00 | 6,219.00 |
|
Gross Profit
|
41,121.51 | 54,127.00 | 63,937.00 | 46,731.00 | 23,208.00 |
|
Operating Expenses
|
27,682.63 | 32,481.90 | 42,828.00 | 40,863.00 | 26,126.00 |
|
Operating Profit (EBIT)
|
14,333.98 | 39,830.40 | 25,525.00 | 10,927.00 | -1,252.00 |
|
Other Income
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Profit before Tax
|
12,645.68 | 34,769.20 | 17,737.00 | 4,762.00 | -2,533.00 |
|
Provision for Tax
|
2,630.63 | 7,189.50 | 1,642.00 | 2,313.00 | 1,330.00 |
|
Profit after Tax (Net Income)
|
10,033.05 | 27,579.70 | 16,095.00 | 2,453.00 | -3,863.00 |
|
Minority Interest
|
18.00 | 0.00 | 0.00 | 6.00 | 0.00 |
|
Consolidated Profit
|
2,409.00 | 6,636.00 | 5,116.00 | 2,963.00 | 0.00 |
Liabilities ($ Mln)
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
37,228.00 | 40,271.00 | 81,529.00 | 0.00 | 13,038.00 |
|
Minority Interest
|
18.00 | 0.00 | 0.00 | 6.00 | 0.00 |
|
Non-Current Liabilities
|
47,060.00 | 60,805.00 | 60,439.00 | 0.00 | 26,450.00 |
|
Current Liabilities
|
32,525.00 | 46,996.00 | 55,457.00 | 0.00 | 12,002.00 |
|
Total Liabilities
|
115,569.20 | 112,476.00 | 199,210.00 | 136,866.00 | 59,023.00 |
Assets ($ Mln)
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
88,402.00 | 82,809.00 | 141,074.00 | 0.00 | 34,855.00 |
|
Current Assets
|
28,747.00 | 65,263.00 | 56,351.00 | 0.00 | 16,554.00 |
|
Total Assets
|
115,569.20 | 112,476.00 | 199,210.00 | 136,866.00 | 59,023.00 |
|
Total Debt*
|
48,310.00 | 49,503.00 | 44,651.00 | 0.00 | 26,231.00 |
|
Net Current Assets
|
-3,778.00 | 18,267.00 | 894.00 | 0.00 | 0.00 |
Cashflow ($ Mln)
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
19,242.03 | 16,813.00 | 24,530.00 | 16,472.00 | 10,019.00 |
|
Cash Flow from Investing Activities
|
-4,901.98 | -10,972.00 | -23,588.00 | -13,741.00 | -4,793.00 |
|
Cash from Financing Activities
|
-14,943.13 | -2,213.00 | -5,539.00 | -1,922.00 | -7,745.00 |
|
Net Cash Inflow / Outflow
|
-- | -- | -- | -- | -- |
Ratios
Profitability Ratios
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
17.74 | 35.32 | 22.56 | 19.45 | 18.17 |
|
ROE (%)
|
26.54 | 77.18 | 19.78 | 10.72 | -21.14 |
|
ROA (%)
|
6.94 | 15.75 | 6.48 | 3.10 | -5.57 |
|
EBIT Margin (%)
|
25.26 | 49.24 | 18.85 | 0.21 | -4.91 |
|
Net Margin (%)
|
17.82 | 31.90 | 16.20 | 3.64 | -12.47 |
|
Cash Profit Margin (%)
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Growth Ratios
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-0.12 | 45.51 | 7.80 | 4.79 | 6.54 |
|
EBIT Growth (%)
|
-18.88 | 70.32 | -41.80 | -99.40 | -113.96 |
|
Net Profit Growth (%)
|
-30.29 | 49.79 | -35.92 | -87.11 | -147.63 |
|
EPS Growth (%)
|
-28.45 | 50.65 | -36.38 | -87.04 | -148.77 |
|
Book Value Growth (%)
|
-14.48 | 70.28 | 2.00 | -- | -39.33 |
Valuation Ratios
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
18.92 | 46.76 | 18.83 | 14.35 | 18.07 |
|
Price / Book Value
|
5.77 | 36.37 | 6.19 | 4.98 | 6.77 |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
12.68 | 31.56 | 12.97 | 10.54 | 12.45 |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
0.99 | 1.17 | 0.44 | 0.96 | 0.00 |
|
Short term debt to equity ratio
|
0.27 | 0.06 | 0.11 | 0.05 | 0.19 |
|
Current Ratio
|
0.88 | 1.39 | 1.02 | 1.54 | 1.38 |
|
Quick Ratio
|
0.70 | 1.00 | 0.74 | 1.30 | 1.22 |
|
Interest Coverage
|
9.02 | 30.52 | 23.23 | 4.37 | -1.51 |
Operating Efficiency Ratios
| Novartis AG - ADR | Eli Lilly and Company (LLY) | Johnson & Johnson (JNJ) | Merck & Company Inc (MRK) | Gilead Sciences (GILD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
17.69 | 29.18 | 19.11 | 0.00 | 16.16 |
|
Asset Turnover
|
0.39 | 0.49 | 0.40 | 0.85 | 0.45 |
|
Receivable days
|
63.79 | 93.67 | 70.00 | 64.57 | 57.89 |
|
Inventory Days
|
159.98 | 352.51 | 160.77 | 128.14 | 102.06 |
|
Payable days
|
120.44 | 142.23 | 134.61 | 85.14 | 45.35 |
|
Cash Conversion Cycle
|
103.33 | 303.95 | 96.16 | 107.57 | 114.61 |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
